Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia.

B J Druker1, C L Sawyers, R Capdeville

  • 1Oregon Health and Science University, Portland, OR 97201-3098, USA.

Hematology. American Society of Hematology. Education Program
|November 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying canonical and replicable multi-scale intrinsic connectivity networks in 100k+ resting-state fMRI datasets.

Human brain mapping·2023
Same author

Knight Scholars Program: A Tiered Three-Year Mentored Training Program for Urban and Rural High School High School Students Increases Interest and Self-Efficacy in Interprofessional Cancer Research.

Journal of STEM outreach·2023
Same author

A method for estimating and characterizing explicitly nonlinear dynamic functional network connectivity in resting-state fMRI data.

Journal of neuroscience methods·2023
Same author

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Moving beyond the 'CAP' of the Iceberg: Intrinsic connectivity networks in fMRI are continuously engaging and overlapping.

NeuroImage·2022
Same author

Electrophysiological investigation of reward anticipation and outcome evaluation during slot machine play.

NeuroImage·2021
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Treatment options for chronic myelogenous leukemia (CML) are rapidly evolving. This review covers imatinib mesylate (STI571), interferon, and stem cell transplants to guide clinical decisions.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myelogenous leukemia (CML) treatment landscape is rapidly evolving.
  • New therapies like imatinib mesylate (STI571) and refined stem cell transplant protocols offer more options.
  • Clinicians and patients face complex choices in CML management.

Purpose of the Study:

  • To review clinical results and resistance mechanisms of imatinib mesylate (STI571) in CML.
  • To provide practical guidance on STI571 administration, including dosage and side effect management.
  • To summarize recent data on interferon-based regimens and allogeneic stem cell transplants for CML.

Main Methods:

  • Review of clinical trial data for STI571 (imatinib mesylate).
  • Analysis of ongoing research into STI571 resistance.

Related Experiment Videos

  • Compilation of recent findings on interferon-based CML treatments.
  • Summary of outcomes from allogeneic stem cell transplants, including reduced intensity conditioning.

    • Main Results:

    • STI571 demonstrates significant clinical efficacy in CML treatment.
    • Understanding of STI571 resistance mechanisms is crucial for long-term management.
    • Interferon-based regimens and stem cell transplants remain important therapeutic options.
    • Comparative data is presented to aid in treatment selection.

    Conclusions:

    • A comprehensive overview of emerging CML treatments is provided.
    • Guidance is offered to clinicians and patients in selecting optimal CML therapy.
    • The integration of STI571, interferon, and stem cell transplantation is discussed for personalized CML management.